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Item M P Difl p-value
Visitsand drugs 1861 1646 15 NS
Starl up costs (inclM) 972 0 972 NA
Hospitalcsre (exd Htx) 2687 4448 -1762 >0.05
Hesrttrsneplantation (Hti) 141t 13740 -12329 <0.001
Totslcosts (inclHfx) 6931 20034 -13104 <0.001
Conclusion: The uae of metoprolol in a population of congestive heart
failure due to idiopathic dilated cardiomyopathy (mainly NYHAclasa II and Ill
patients) is highly coat effective and should therefore always be considered
as complementary to reduce morbidity and health care coata.
m1017145 Impact of Carvedilol Therapy for Heart Failure onCosts of Cardiovascular-Related Hospitalization
G.Oster, J. Menzin, R.E. Richner, S. Young, M. Vera, MB. Fowler. Po/icy
Arra/ysis Inc., Brocddine,MA; SrrrithKhre Bescham, Philadelphia, PA, USA
In the recently-completed U.S. Carvedilol Heart Failure Trials Program, the
multiple-action, neurohormonal antagonist oarvadilol was found to reduce
mortality and cardiovascular-related hospitalization over a mean follow-up
period of 6.5 months oompared to placetm in patients with symptomatic con-
gestive heart failure (CHF) rsoeiving treatment with angiotensin-converting
enzyme inhibitors, digoxin, and diuretioa. We undertook an economic eval-
uation in conjunction with this program to examine the impact of cwvedilol
therapy on the mate of cardiovascular-related hospitalization. The utiliza-
tion of all cardiovascular-related inpatient services was documented for all
eubjects in this program, and costs (not charges) were aseigned using sec-
ondary data. The mean total cost of all cardiovascular-related admissions
was 62% lower among patients receiving cewedilol compared to those re-
ceiving placebo (mean + SD) $Iw + 6667vs $4327+ 20507 msP@ivelY)
(p= 0.01 by Wilcoxon rank-sum teat). Few-four percent ($1164) of these
aavings refleqted reduced numbers of cardiovascular-related admissions.
The remainder was attributable to reduced numbers of days in intensive-
care units per admission (1.47 + 2.85 vs 4.83 + 16.66). Cost aavings were
similar in patient aubgroupa defined by age, gender, etiology of CHF,ejection
fraction, and New York Hearl Ass~iation (NYHA) Class.
WI f3fectsofLong-TermCarVedilOIAdminiatration
in Patients with Idiopathic Dilated
Cardiomyopathy
M. Metra, S. Ncdari, D. Raccagni, M. Garbellini, E. Boldi, M. Grigolato,
F. Roeaelli, R. Zanini, L. Dei Cas. Cardiology, University of Brescia, /ta/y
Follow-up duration in previous controlled trials regarding cswedilol (carv)
in heart failure (HF) was s 1 year. We report the effects of long-term csrv
administration to pts with HF,first recruited ina4 months, placebo-controlled,
trial. All the 20 pts initially randomizedfo caw continued treatment with this
drug. Among them, 4 died (3 for cardiac and one for noncardiac causes)
and 2 undarwent hearl Tx. Among the 20 pts initially on placebo, 5 died for
cardiac causes, 3 underwent heatt Tx and 4 wera crossed over to carv for
worsening HF; the remaining 8 were used as control group. All pts were on
dig, fur and ACE-i and were asseased by MUGA, bicycle CPX testing and
MLHF questionnaire at baaeline, after 4 rots, 1year and 44 + 12 mts (range
40 to 53) of therapy. No difference was present at baseline between the two
groups. In the control group, LV EDVI increased from 126+62 to 136 +53
and 158 + 62 ml/m2 after 1 and 4 years; no other significant change was
found. Reeulte in the pts on caw are reported in the table (*p < 0.01).
EF (%) EDVI Peek V02 NYHA MLHF
BS 22* 6 147 *54 15.2 + 3.6 2.6 + 0.5 42& 16
4 mts 34* 11* 139 +51 t6.4 +4.0 1,9 * 0.3” 26+20
1year 37* 11* 113 +42 17,3 & 5.6 1.9+0.8” 30 i 22
4 ys. 37 i 13* 101 +44* 17,2 &5.3 2.0+ 1.0” 32• 24
These results show that sew may improve LV function and symptoms of
patienta with HF also during long-term therapy.
m1017147 Ambulatory Intermittent 6-month Low-doeaDobutamine Infusion in Severe Heart Failure:
DICE Multicenter Trial
DICE Coilaboretive Group. LWifuto“M. Negri”, Mi/ano, /ta/y
3S pts clinically atable for at least 48 hours with standard treatment, NYHA
claee Ill or IV, oardiac index (Cl) s 2.2 I’min–l ‘m’2 and EF s 30%, were
randomized in 13 Cardiology Departments, 19 to ambulatory intermittent
dobutamine (D) and 19 to optimal standard treatment (controls, C). D was
infused at 2,5 &g*kg-l ‘rein-l with a portable pump 48 h/week for 6 months.
Follow up visits were at 8 weeks and at 6 months. Primary study endpoint
was 2 hospitalizations for worsening of CHF (2H-CHF); changes in NYHA
class, of 6 minute walking test (6 mWT) and mortality were secondary end
points. Baseline characteristics were age 65 + 9 y (mean + SEM), NYHA
class 111/lV18/20, ejection fraction 22 + 1°/., Cl 1.89 + 0.07 1*rein-l ‘m-2
without difference between treatment groups. The primary endpoint of z 2H-
CHF was reached by 4 C pts, but by none in D group; NYHA class improved
significantly (table) only in D, while 6 mWT did not change vs baseline (298
+ 35 C, 299 + 29 D). 3 pts in C group died and 5 in D, p = ns (2 pts during
drug D infusion). Median time to death was 62 and 94 days in C and D
respectively,3 pts in D group underwent heart transplantation. Protocol was
discontinued in D group for severe ventricular arrhythmias (1 pt), consent
withdrawal (1 pt), and intolerance to infusion syatem (1 pt). In 3 D pts drug
dose waa increaaed to 5 Wg”kg-’”min-’ because of CHF.
No. group base 19C/19D 8w-base t8C/12D 6m-base 13C/6D
NYHA class c 3.58 + 0.11 –0.37 * 0,39 –1 .08+ 0,17
D 3.53 * 0.11 –1 * 0,249 2 + 0.679
Cl (1rein-l m-2) C 1.63 + 0.07 –0.09 * 0.09 n.a.
D 1.94 + 0.08 0.29 + O.leQ n.a.
mean + SEM; ‘p <0.05 vs C; ma.: notassessed.
6-month intermittent low-dose D was well tolerated, improved NYHAclaas
and Cl, and decreased hospitalizations in patients with severe CHF, without
the significant increase in mortality found with higher D doses in other studiea.
m1017148 Action of Amlodipine on Cytokine Levels: The
PRAISE Heart Failure Trial
E.R. Mohler Ill, L.C. Sorenson, J.K. Ghali, D. Schocken, P.W.Willis,
J.A. Bowers, A.B. Cropp, M.L. Pressler. The University of Penrwy/vania,
Phi/ade/phia, PA, USA
The molecular mechanism for progression of chronic heart failure (HF) may
involve cyfokine over-expression. in the PRAISE trial, we U8ed ELISA to aa-
say plasma levels of tumor necrosis factor alpha (TNF,n = 92) and interiaukin
6 (IL-6, n = 62) in patients with NYHA Class III-IV HF randomized to amlcdip-
ine (Amlo; 10 mg/day) or placebo (Plac). Baseline Amlo and Plac groups did
not differ in demographic and cytokine levels. Plasma levels (mean + SE)
of TNF were 5.69 + 0.32 pr#ml and IL-6 were 9.23 + 1.26 pg/ml at base-
Iina. These levels were elevated 6-times and 10-times, respectively, that of
controla (P < 0.001).
CytokineLevele (mean + SE in pg/ml)
Group Baseline 8 Weeks 26 Weeks
TNF Plac 5.2 & 0.4 5,5 * 0.4 5.5 & 0.4
TNF Amlo 6.3 & 0.6 7,2 & 1.2 6.6 * 1.0
IL-6 Plac 5.6 + 0.6 8.6 * 1.5 8.0 + 2.2
TNF Amlo 9.9 + 2.9 8.5 & 2.3 6.9 + 1.8
TNFdid not change significantly over the 26 week period (p= 0.69). How-
ever, IL-6 levels were significantly lower at 26 weeks in patienta treated with
amlodipine vs. placebo (p = 0.007, Signed Rank Test). Significant variables
predictive of suwival were IL-6 (p = 0.018) and NYHA clase (p = 0.025).
Thus, amlodipine seams to cause a reduction in IL-6 levels in patients with
congestive heart failure.
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\ 1018-31 I MitralValveMorpholOWandFUntiiOnbefOreand
afterLeftVentricularRemodelingSurgery
G.M. Scalia, P.M.McCarthy, R.C. Starling, A.J. Morahead, R.L. Vargo,
TM. Buda, J.D. Thomas. C/eve/and Clinic Foundation, C/eve/and, 0/-/, USA
The left ventricular remodeling’procedure (LVR) for congestive hearI failure
involves excision of the entire posterolateral LV wall with approximation of
the papillary muscles. The resultant lengthening of the chordal apparatus
has been countered by a unique valvuloplasty procedure: tacking of the mid-
portion of the anterior and posterior leaflets, with or without annuloplasty ring
support.
JACC February 1997
Results: 15 pts have undergone LVR, age 34-88 (mean 50.2 yrs, 11
male), exclusively for idiopathic cardiomyopathy. Pre-operatively, 11/15 had
grade 3+ or 4+ mitral regurgitation (MR), related to annular dilation and poor
coaptation. One patient had StJude replacement. 10/11pts had a Cosgrove-
Edwards annuloplaaty ring placed. 14 pts had the tack stitch placed (see fig
arrow). Post-pump, all pts had 0+ to trace MR. The unique double-orifice
appearance did not cause stenosis. One patient required transplantation
of the anterolateral papillary muscle to allow a larger myocardial excision,
intermediate follow-up (mean 28 days) showed 12/15 had trivial MR, 2+ MR
in 2 and 3+ in 1.
Conclusions: Left ventricular remodeling surgery grossly distork papillary
muscle geometry. A unique valvuloplasfy involving a stitch between the mid-
portion of the leaflets with or without annuloplasty provides excellent valve
competence without stenosis.
I 1018-321 NewlnsightslntO the Path~,~gY~f~gene~ative
Mitral Valve Incompetence. A Hiatomorphometric
Study
P.Fomes, J.-F. Fuzellier, D. Tixier, P.Sruneval, A.F. Carpenter. Fk5pita/
Broussais, Paris, France
Predietabilifyof the results of mitral valve repair (MVR) for degenerative mitral
valve incompetence (DMI) is an important source of concern. The aim of our
study was to examine quantitatively the histological changes in degenerative
mitral valves from 130 patients (pts) who underwent MVR for DMI. Pts were
divided into 4 groups according to the clinical patterns and operative findings
as followa: Barlow’a Disease (BD) (n = 39), Fibroalastic Deficiency (FED) (n
= 44), Marfan Syndrome (MS) (n = 15) and undetermined condition (n = 32).
The specimens obtained at surgery were examined under blind conditions.
Histologic scores of severity were applied to lesions (myxoid infiltration,
collagen and elastic fiber lesions): O: normal, 1: minimal, 2: mcderate, 3:
severe lesions. Statistically, a discriminant analysis claesifiad the pts into the
groups defined clinically, according to the histologic scores. Results.’All pts
with the MS were recognized by the statistical procedure, as were all but
one FED pts. There was no clear distinction between the histologic patterns
of MS and BD. When the age of the pts and the size of the prosthetic ring
usad for repair were added to the histologic parameters, all pts were rightly
classified. Half of the 32 pts with no determined disease were considered
atatistieally to have distinctive clinical and histological patterns.
Our histomorphometric data show a clear distinction between FED and
other conditions. Histological examination of the excised valves is of im-
portant use for the predictability of the success of valve repair in different
diseases responsible for DMI. ‘
m101833 Multivariete Predictors of BiomechanicalPropetiies in Myxomatous Mitral Valve Dieeaae
C.S. Breburda, 1.Vesely, A.R. Brewer, N.B. Ratliff, D.M. Cosgrove Ill,
J.D. Thomas, B.P. Griffin. The Cleveland C/inic Foundation. Cleveland, OH,
USA
Structural abnormalities in valve tissue are thought to be responsible for
leaflet prolapse and regurgitation in myxomatous valve disease. We wished
to determine the independent predictors among clinical and echo data of
biomechanical propeflies (BMP) of mitral tissue excised at valve repair.
Methods: We studied 32 pts (28 males), mean age 57 + 10 (SD) years
undergoing mitral valve repair. An echo score of leaflet thickness, leaflet
and annular calcification, redundancy, degree of prolapse and tricuspid valve
(TV) involvement was generated. Mitral leaflet thickness (LT) and LV size
was measured by echo. We determined BMP of the valve tissue excised at
surgery: geometry (size, weight, volume), atiffness and failure variables. We
used multiple regression analysis to determine the independent predictors of
BMP among the clinical and echo variables.
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Results:
BMP IndependentPredictors # D
Geometry Echoscore 0.58 <0.001
Stiffness(kPa) LV diameter, LT 0.62 <0.0001
FailureTension(N/mm) W redundancy,LT 0,5s <0.0001
Murmurduration
Conclusions: 1. Much of the variability in structural abnormalities of myx-
omatous tissue is predicted by easily acquired clinical and echo variables. 2.
Predicting structural abnormality noninvasively may prove useful in assess-
ing disease severity and timing of intervention.
w] Echocardio~raphy CanldentifyPatientefor Mitrai
Valve Repair
D.A. Cusi6k, R.J. Blaber, E.S. Dawson, J.H. Sanders, R.J. Morris,
F.A.Chaudhry. Northwestern University Chicago, IL, USA, A/ksgheny
University of the Hea/th Sciences, Philadelphia, PA, USA
Mitral valve (MV) repair decreases the incidence of pathologic complications
when compared to MV replacement. Echocardiographic variables that predict
the surgical decision to perform MV repair have not been well determined.
We retrospectively analyzed transesophageal achocardiograms (TEE) of 51
pts (35 MV repair, 18 MV replacement; mean age 57 years, range 20-S2;
27 male and 24 female) with mitral regurgitation who underwent MV surgery
by two surgeons at two institutions. TEE variables included LA size, annular
diameter, mitral annular calcification, leaflet mobility, leaflet thickness, leaflet
length, prolapse or flail leaflet, maximal chordal length, chordal rupture,
severity and characteristics of the mitral regurgitant jet, and left ventricular
size and function.
TranessophagealVarisblesFavoringMtral Valve Repair
Repair Replacement p Value
PoateriorLeaflet Length(mm) 24& 5 16+ 3 <0.0001
AnteriorLeeflet Length(mm) 33* 5 28& 5 <0.01
AnnularDiameter (mm) 43& 7 38& 10 <0.06
ChordalLength(mm) 33A 6 2s + 7 <0.08
Using discriminant analysis, repair versus replacement was correctly pra-
dicted in 45 of 51 (88%) pts with a sensitivity of 88% and epacificity of
94%.
Cc.nc/usions:Transesophageal achocardiography can identify patients
with mitral regurgitation who will undergo MV repair as opposed to replace-
ment.
11018-35Icha~aCte~iStiCsYStO,iCandDiaStO,iCMitra, Leaf,et
Configuration in Patients with Incomplete Mitral
Leaflet Closure: ,Evidence for Mitral Valve
Tethering
Yutaka Otsuji, Leng Jiang, Dan Gilon, Arnold A. Fontaine, Mary
J. Birmingham, Robefl A. Levine. Mass. Genera/ Hospita/, Boston, MA, USA
Competing explanations for mitral regurgitation (MR) with incomplete mi-
tral leaflet (MV) closure (IMLC) include global LV dysfunction vs geometric
changes causing abnormal leaflet tethering. Theae factors often coexist, but
clinical observations provide clues in favor of tethering: 1) systolic anterior
leaflet (AL) abnormal bending, suggesting nonuniform forces from tensad
strut chordae, and 2) diastolic leaflet opening restricted to the line conrweting
IMLC(+) IMLC(–) Control
EF s 30”A EF s 30
AngledAL (syst.) 32136*S 0/22 0/21
Restrictedopening 30/36*# 0/22 0/21
Openingsngle a(g) 16+ 10”# 56& 13* 67 ~ 6
LVEF (“A) 24 k 6* 27+ 4“ 61 k 5
*p s 0.05 tocontr01,#p s o,05t0 IMLC(–)
IMLC(+) PM
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